1,329 calculators and references across 60 specialties, with formula confidence shown up front.
SAVE Post-MI LV Dysfunction Prognostic Score — Explanation and Clinical Context This calculator estimates the prognosis of patients after myocardial infarction (MI) with left ventricular (LV) systolic dysfunction, using key clinical and laboratory parameters repeatedly shown to correlate with mortality and adverse remodeling. The variables include age, LVEF, Killip class, renal function, systolic blood pressure, hear
: Explanation and Clinical Context The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) evaluated the role of implantable cardioverter-defibrillator (ICD) therapy in patients with heart failure and reduced ejection fraction (HFrEF). The study enrolled patients with ischemic or nonischemic cardiomyopathy, NYHA class II–III, and LVEF ≤35%. This calculator provides an approximate estimation of the 3-year all-cause
SCORED Trial (Sotagliflozin) Risk Index — explanation and clinical context This calculator implements a trial-derived risk estimator based on SCORED trial aggregate results. SCORED enrolled adults with type 2 diabetes and chronic kidney disease and reported a primary composite event rate in the placebo arm of approximately 7.5 events per 100 patient-years (≈7.5% per year) and an estimated hazard ratio of 0.74 for the
Seattle Heart Failure Model (SHFM): Explanation and Clinical Context The SHFM is a validated multivariable model to estimate mortality risk in patients with chronic heart failure based on clinical, laboratory, and treatment variables. It was developed using data from the PRAISE I cohort and externally validated in multiple populations. The model calculates a risk score (SHFM Score) using regression coefficients appli
— explanation and clinical context This tool classifies heart failure patients into subpopulations using commonly accepted left ventricular ejection fraction thresholds (HFrEF <41%, HFmrEF 41–49%, HFpEF ≥50%). It then provides directional prognostic information using two well-known validated frameworks as proxies: the MAGGIC risk framework for 1- and 3-year mortality, and the GWTG-HF model for in-hospital mortality r
SOLOIST-WHF Post-HF Benefit Index: Explanation and Clinical Context The SOLOIST-WHF (Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes and Worsening Heart Failure) trial was a landmark study evaluating the dual SGLT1/2 inhibitor sotagliflozin in patients recently hospitalized for acute decompensated heart failure, with or without reduced ejection fraction. This calculator estimates the relative
: Explanation and Clinical Context The STOPDAPT-2 ACS trial evaluated an abbreviated dual antiplatelet therapy (DAPT) strategy (1–2 months followed by clopidogrel monotherapy) versus standard 12-month DAPT in patients with acute coronary syndrome undergoing successful percutaneous coronary intervention. Although the primary endpoint did not demonstrate non-inferiority for the abbreviated therapy regarding the composi
Age (years) Acute coronary syndrome (ACS) presentation? Select Yes No High-bleeding-risk (HBR) criteria met? Select Yes No Complex PCI (yes/no)? Select Yes No STOPDAPT-2 ACS Risk Subgroup Calculator: Explanation and Clinical Context The STOPDAPT-2 family of trials investigated the safety and efficacy of abbreviated dual antiplatelet therapy (DAPT) duration followed by P2Y12 inhibitor monotherapy versus standard 12-mo
STRONG-HF Risk Framework — explanation and clinical context This calculator implements a transparent prototype points system that aggregates commonly reported prognostic features relevant to patients hospitalized for acute heart failure (age, hemodynamics at discharge, NT-proBNP, renal function, potassium, LVEF, recent HF hospitalization, and intensity of guideline-directed medical therapy achieved at discharge). It